The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: Sensory Motor Neuropathy Antibody Panel Ganglioside
The Sensory-Motor Neuropathy Antibody Panel (Gangliosi test contains 1 test with 9 biomarkers.
Sensory-Motor Neuropathy Antibody Panel (Ganglioside)
Includes
Ganglioside GM-1 Antibodies (IgG, IgM), EIA; Ganglioside GD1a Antibody (IgG, IgM), EIA; Ganglioside GD1b Antibody (IgG, IgM), EIA; Ganglioside GQ1b Antibody (IgG), EIA; Ganglioside Asialo-GM-1 Antibody (IgG, IgM), EIA
Clinical Significance
The presence of antibodies to the gangliosides GM1, Asialo-GM1, GD1a and GD1b has been associated with motor and sensorimotor neuropathies. High titers of antibody to GM1 are most typical of multifocal motor neuropathy; however, antibodies to other gangliosides are often present. In most cases of chronic immune neuropathies, anti-ganglioside antibodies are IgM class. IgG antibodies have been reported less often, generally associated with acute conditions. Many reports have found increased anti-asialo-GM1 antibody titers in patients with multifocal motor neuropathy, lower motor neuron disease, sensorimotor neuropathy, or motor neuropathy with or without multifocal block, Guillain-Barré Syndrome, and amyotrophic lateral sclerosis. There may be a relationship between titers of asialo-GM1 antibodies and clinical status in individual patients. In some lower motor neuron disorders, improvement in strength has occurred after therapeutic reduction in anti-asialo-GM1 antibody titers. Polyclonal GQ1b IgG antibody can serve as an aid in the diagnosis of acute ataxia neuropathy with ophthalmoplegia or of Miller-Fisher Syndrome.